Philip J. Lupo, PhD, MPH
Dr. Philip Lupo is a molecular epidemiologist whose research interests include:
- identifying the genes underlying pediatric rhabdomyosarcoma;
- understanding the risk of cancer among children with structural birth defects; and
- characterizing the molecular mechanisms underlying late effects among survivors of childhood cancer.
By studying epidemiology of childhood cancer, we can improve our efforts to reduce the impact of these diseases. The ultimate goal of Dr. Lupo's research is to identify factors that can be used in novel prevention efforts and targeted interventations for childhood cancer.
Dr. Lupo is a molecular epidemiologist and Co-Director of the EpiCenter in the Texas Children’s Cancer and Hematology Centers with a focus on inherited genetic susceptibility to childhood cancer and birth defects, as well as the disrupted developmental pathways that may lead to the overlap of these conditions. He is a member of the Children’s Oncology Group (COG) Epidemiology and Soft Tissue Sarcoma Committees. Additionally, he is Chair of the National Birth Defects Prevention Network (NBDPN) Data Committee and serves on the NBDPN Executive Committee.
Dr. Lupo has a particular interest in the use of novel epidemiologic study designs and methods in determining the etiology of rare pediatric conditions. He is currently working closely with investigators in COG to develop a research program in the epidemiology of rhabdomyosarcoma and is the principal investigator (PI) of the COG-supported Genetics of Embryonal and Alveolar Rhabdomyosarcoma Study (GEARS).
Dr. Lupo is also an active collaborator with the Centers for Disease Control and Prevention (CDC)-funded National Birth Defects Prevention Study (NBDPS) and is part of a multidisciplinary team of experts assessing the intersection of childhood cancer and birth defects. As part of this, Dr. Lupo is the PI of the Genetic Overlap Between Anomalies and Cancer in Kids (GOBACK) Study, a multistate consortium evaluating the risk of cancer in children with birth defects.
Another aspect of Dr. Lupo’s research is understanding the molecular mechanisms of the long-term consequences of pediatric cancer treatment (i.e., late effects). He is a collaborator with several ongoing studies in the Childhood Cancer Survivor Study (CCSS) and is a member of the COG Outcomes-Survivorship Committee. As a previous recipient of the CCSS Career Development Award, Dr. Lupo has been leading an effort to determine the role of DNA methylation on late effects in survivors of childhood cancer. The ultimate goal of Dr. Lupo’s research is to discover factors that can be used in new prevention efforts and targeted interventions to limit the adverse consequences of adverse pediatric outcomes.
Health conditions researched: Rhabdomyosarcoma, cancer risk in children with birth defects, epidemiology of acute lymphoblastic leukemia, molecular epidemiology of late effects in survivors of childhood cancer